MAIN


1996-2019. All Rights Reserved. Online Journal of Bioinformatics . You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the  before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJB publications. This article may be copied once but may not be, reproduced or  re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the Higher Education Research Data Collection (Australia). Linking: To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.


OJBTM

 Online Journal of Bioinformatics  

  Volume 16 (2): 156-178, 2015.


In Silico 2, 5- disubstituted-1, 3, 4-oxadiazole antibacterial activity.

 

Pyde Acharya Nagarjun1, Nagaraja Rao P2*

 

1Department(s) of Microbiology, 2Zoology, Osmania University, Hyderabad, India

 

ABSTRACT

 

Nagarjun PA, Rao PN., In Silico 2, 5- disubstituted-1, 3, 4-oxadiazole antibacterial activity, Onl J Bioinform., 16 (2): 156-178, 2015. Docking of synthetic drug derivatives with bacterial cell wall receptor Listeria nuclear targeted protein A (LNTA) may inhibit Listeria monocytesis. Active sites in the protein were residues TYR18, TYR21, LYS22, GLN25, ARG26, ARG98, GLY101, ASP102, PHE104, SER105, ARG106, TYR108, ARG109, ASP111, PHE112, ALA113, MET115, SER116, GLN118, LEU119. A designed 2,5 disubstitued 1,3,4-oxadiazole was docked to LNTA using Open Eye software. Results show that of 50 ligands, 23 docked to LNTA suggesting that these ligands may have anti-bacterial activity. The ligand N-(3-{[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]thio}propyl)-4-Methylbenzene sulfonamide showed most activity.

 

Key words: Listeria, Drug Designing, Docking Studies, Oxadiazoles.


MAIN

 

FULL-TEXT (SUBSCRIPTION OR PURCHASE TITLE $25USD)